JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS
AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
A&A International Anesthesia Research Society
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Connor, C. J.
Right arrow Articles by Tuman, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Connor, C. J.
Right arrow Articles by Tuman, K. J.
Anesth Analg 1999;89:1101
© 1999 International Anesthesia Research Society

CARDIOVASCULAR ANESTHESIA

The Impact of Renal Dysfunction on Aprotinin Pharmacokinetics During Cardiopulmonary Bypass

Christopher J. O’Connor, MD, Douglas V. Brown, MD, Michael Avramov, MD, PhD, Steven Barnes, MD, Heather Nath O’Connor, MD, and Kenneth J. Tuman, MD

Department of Anesthesiology, Rush Medical College, Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois

Address correspondence and reprint requests to Christopher J. O’Connor, MD, Department of Anesthesiology, Rush Medical College, Rush-Presbyterian-St. Lukes Medical Center, Chicago, Illinois 60612. Address e-mail to coconnor{at}rpslmc.edu


   Abstract
Top
 Abstract
Introduction
 Methods
 Results
 Discussion
 References
 
Aprotinin is a serine protease inhibitor that undergoes metabolism in the kidney. Because elimination is almost entirely renal, the clearance of aprotinin may be reduced in patients with renal insufficiency. Unfortunately, there are no data regarding aprotinin pharmacokinetics in cardiac surgical patients with renal insufficiency or end-stage renal disease (ESRD) undergoing cardiopulmonary bypass (CPB). We, therefore, determined the clearance (ApCl) and elimination half-life (T1/2) of aprotinin in 26 cardiac surgical patients with normal and abnormal renal function (creatinine clearance [CrCl] 0–122 mL/min) undergoing CPB. Subjects were given a 2 million kallikrein inhibiting unit (KIU) initial dose of aprotinin, followed by a 0.25 million KIU/h infusion. No aprotinin was added to the pump prime. Plasma aprotinin concentrations were sampled at 30 min after completion of the loading dose, 30 and 60 min after the onset of CPB, at the end of CPB, and at 8, 24, and 32 h after completion of the loading dose. ApCl was directly related and the elimination T1/2 inversely related to CrCl (r = 0.75 and 0.42, respectively). In patients with a CrCl >50 mL/min, the T1/2 and ApCl were 7.8 h and 53 mL/min, respectively, compared with 19.9 h and 25 mL/min (P < 0.05, P < 0.002, respectively) for patients with ESRD. In conclusion, ApCl is reduced, and T1/2 is prolonged in patients with renal insufficiency or ESRD undergoing CPB. Dosing modifications may be necessary for patients with abnormal renal function undergoing cardiac surgery.

Implications: Because aprotinin is metabolized and eliminated in the kidney, its clearance may be reduced in patients with renal insufficiency. Our data suggest that aprotinin clearance is reduced, and aprotinin half-lives are prolonged in patients with renal insufficiency undergoing CPB. Dosing modification may therefore be indicated when aprotinin is administered to these patients for cardiac surgery.


   Introduction
Top
 Abstract
 Introduction
Methods
 Results
 Discussion
 References
 
Aprotinin is a naturally occurring serine protease inhibitor that reduces blood loss and transfusion requirements when used during cardiac surgery (1). It is filtered by the kidney and metabolized in the proximal convoluted tubule, with the rate of excretion directly proportional to the filtered load through the glomerulus (2). Since aprotinin elimination is almost entirely renal, its clearance may be reduced in patients with renal insufficiency.

Unfortunately, the pharmacokinetics of aprotinin in patients undergoing cardiopulmonary bypass (CPB) are poorly defined, and data from individuals with renal insufficiency are lacking. A previous report determined that plasma aprotinin levels were elevated for prolonged periods and aprotinin clearance reduced when aprotinin was administered in standard doses to a single patient with end-stage renal disease (ESRD) (3). This finding suggested that altered aprotinin pharmacokinetics might produce unpredictable and excessively high plasma levels in patients with renal dysfunction using standard dosing schedules.

To clarify the influence of renal dysfunction on aprotinin elimination, we studied the pharmacokinetics of aprotinin in cardiac surgical patients with both normal and abnormal renal function undergoing CPB.


   Methods
Top
 Abstract
 Introduction
 Methods
Results
 Discussion
 References
 
After receiving approval from our institutional review board and informed, written consent, patients undergoing cardiac surgery requiring CPB were enrolled in the study. Exclusion criteria included a known adverse reaction to aprotinin, pregnancy, age <18 yr, the presence of liver disease, emergency procedures, or procedures employing hypothermic circulatory arrest. Baseline creatinine clearance (CrCl) was calculated using the Cockcroft-Gault equation as follows: Go


Go


Anesthesia consisted of fentanyl, midazolam, and isoflurane in 100% oxygen. After induction of anesthesia, each patient received a 10,000 kallikrein inhibiting unit (KIU) test dose of aprotinin. If no evidence of anaphylaxis was observed, a loading dose of 2 million KIU was administered for 30 min at the time of skin incision, followed by a continuous infusion of 0.25 million KIU/h until closure of the chest. The CPB pump prime consisted of 2 L of lactated Ringer’s solution containing 200 mL of 20% mannitol, 100 mL of 25% albumin, and 50 mL of sodium bicarbonate. No aprotinin was added to the pump prime. Standard nonpulsatile CPB using pump flow rates of 2 to 2.5 L · min-1 · m-2, blood/crystalloid cardioplegia at 8– 10°C, systemic temperatures of 28–32°C, and {alpha}-stat pH management were used for all patients. Ultrafiltration was not employed. Porcine heparin was used for anticoagulation, and protamine was used for heparin reversal at the completion of CPB.

Blood samples for aprotinin concentrations were obtained at the following intervals: 30 min after completion of the loading dose (LD + 30); 30 and 60 min after the initiation of CPB (CPB + 30 and CPB + 60, respectively); at the completion of CPB (end-CPB); and at 8 (LD + 8), 24 (LD + 24), and 32 h (LD + 32) after completion of the loading dose. Samples were placed in tubes containing sodium ethylenediamine tetraacetate, immediately placed on ice, centrifuged, and the resultant plasma was stored at -20°C until assayed. Plasma samples were analyzed using a commercial chromogenic assay (Unicorn Diagnostics Ltd., London, UK). Plasma samples were first treated with acetone to remove the effect of serine protease inhibitors and were then diluted with buffers containing {alpha}2-macroglobulin and factor XIIa inhibitors. Purified kallikrein was then added to complex with aprotinin. Residual kallikrein activity was measured photometrically by the liberation of p-nitroaniline, whose concentration is inversely proportional to the concentration of aprotinin (5). Blood samples for thromboelastography (TEG) were drawn after the induction of anesthesia and at 24 h after completion of the aprotinin loading dose. TEG results were assessed for the development of a hypercoagulable state, as measured by the maximal amplitude, the reaction time, and the clot lysis index at 30 min.

The following preoperative demographic and laboratory data were recorded: patient age, weight, gender, coexisting medical conditions, the need for dialysis, and baseline levels of hemoglobin, serum creatinine, blood urea nitrogen (BUN), albumin, serum glutamic oxaloacetic transaminase, glutamic pyruvic transaminase, bilirubin, and CrCl. Intraoperative variables that were recorded included the cardiac index at the end of CPB, urine volume, the duration of aortic cross-clamping and CPB, the lowest bladder temperature and the duration of the hypothermia, the lowest pH during CPB, total fluids and blood products administered, and the total dose of aprotinin used. Variables recorded during the postoperative period included the BUN and creatinine on the first three mornings after surgery, 24-h blood product requirements, and the cardiac index 24 h after the completion of the loading dose. Patients with dialysis-dependent renal failure were dialyzed at the discretion of the nephrology service, and the timing and type of the first dialysis (peritoneal or hemodialysis) were recorded.

Pharmacokinetic variables were calculated using noncompartmental methods. Assuming first-order elimination, areas under the aprotinin concentration-time curve (AUC) were determined using the linear trapezoidal rule with extrapolation to infinity (6). The terminal elimination rate constant, {kappa}, was calculated from the 8, 24, and 32 h samples, and the terminal elimination half-life (T1/2) was determined by dividing 0.693 by {kappa}. Aprotinin clearance (ApCl) for each patient was calculated by dividing the total IV aprotinin dose by the corresponding AUC.

The relationship between ApCl and CrCl, and between T1/2 and CrCl, were evaluated by linear regression analysis. In addition, CrCl was compared with ApCl and T1/2 according to subgroups of CrCl, as follows: Group 1, CrCl 0 mL/min (patients with ESRD requiring dialysis); Group 2, CrCl 1–25 mL/min; Group 3, CrCl 26–50 mL/min; and Group 4, CrCl > 50 mL/min. Values for ApCl, T1/2, perioperative variables, and TEG measurements are reported as mean ± SD and are compared among and within groups using analysis of variance. Post hoc testing was performed using independent sample (among groups) and paired sample (within groups) Student’s t-tests corrected for multiplicity at {alpha} = 0.05 when analysis of variance identified differences with P < 0.05.


   Results
Top
 Abstract
 Introduction
 Methods
 Results
Discussion
 References
 
Twenty-nine patients were enrolled in the study. Three patients were excluded because of inadequate sample collections. Of the three patients with ESRD, two were receiving hemodialysis, and one was treated with peritoneal dialysis. In the first two patients, hemodialysis was performed on the first postoperative day before the final aprotinin sample was drawn. For the last patient, peritoneal dialysis was started after the final sample was drawn.

There was a significant direct relationship between CrCl and ApCl (r = 0.75, P < 0.01) (Figure 1) and a significant, albeit weaker, inverse relationship between CrCl and T1/2 (r = 0.42, P < 0.05) (Figure 2). ApCl was significantly greater (P < 0.002) in patients with a CrCl > 50 mL/min compared with the remaining groups, whereas T1/2 was significantly prolonged in patients with ESRD compared with patients with a CrCl > 50 mL/min (19.9 vs 7.8 h, P < 0.05) (Figure 3). Plasma aprotinin concentrations for each sampling interval are shown for each CrCl group in Figure 4.



View larger version (13K):
[in this window]
[in a new window]
  		Figure 1. Linear regression analysis of the correlation between aprotinin clearance (ApCl) and creatinine clearance (CrCl). P < 0.01.

 


View larger version (12K):
[in this window]
[in a new window]
  		Figure 2. Linear regression analysis of the correlation between aprotinin elimination half-life (T1/2) and creatinine clearance (CrCl). P < 0.05.

 


View larger version (19K):
[in this window]
[in a new window]
  		Figure 3. Relationship between creatinine clearance (CrCl), aprotinin clearance (ApCl), and aprotinin elimination half-life (T1/2) for different subgroups of CrCl.

 


View larger version (18K):
[in this window]
[in a new window]
  		Figure 4. Plasma aprotinin concentrations for the different subgroups of creatinine clearance (CrCl). Error bars are the standard error of the mean and are shown only for selected patients.

 
Baseline bilirubin, serum glutamic oxaloacetic transaminase, and glutamic pyruvic transaminase values were within normal limits for all patients (Table 1). Serum albumin levels were lower in patients with ESRD compared with the remaining groups. Aortic cross-clamp time was significantly longer in Group 1 versus Groups 3 and 4, while CPB time was significantly longer in Group 2 versus Group 3. There was also a larger number of packed red blood cells transfused intraoperatively in Group 2 versus Group 4. Excluding patients with ESRD receiving dialysis in Group 1, there were no significant changes in the available BUN or serum creatinine levels from baseline through postoperative day (POD) 3 within groups, as follows: BUN (mg/dL)/creatinine (mg/dL) baseline versus POD 1 through POD 3 for Group 2: 38 ± 9/2.9 ± 0.7 versus 35 ± 16/2.6 ± 0.8, 42 ± 16/2.8 ± 1.0, and 46 ± 19/2.7 ± 1.6 (P < 0.84 and P < 0.99, respectively); Group 3: 26 ± 11/1.8 ± 0.8 versus 24 ± 14/1.7 ± 0.7, 24 ± 12/1.4 ± 0.4, and 20 ± 6/1.3 ± 0.4 (P < 0.83 and P < 0.66, respectively); and Group 4: 21 ± 10/1.1 ± 0.4 versus 17 ± 8/1.1 ± 0.3, 23 ± 12/1.2 ± 0.5, and 22 ± 10/1.0 ± 0.4 (P < 0.49 and P < 0.92, respectively). Baseline and 24-h TEG data are presented in Table 2. TEG values were unchanged from baseline to 24 h for each group. Complete TEG measurements were not available for one patient in Group 1 and three patients in Group 4, and these were excluded from analysis.


View this table:
[in this window]
[in a new window]
  		Table 1. Perioperative Variables
 

View this table:
[in this window]
[in a new window]
  		Table 2. TEG Values at Baseline and 24 h
 

   Discussion
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
References
 
These data indicate that ApCl is reduced and aprotinin elimination T1/2 is prolonged in cardiac surgical patients with renal insufficiency or ESRD undergoing CPB. ApCl was significantly reduced when the CrCl was < 50 mL/min, whereas, on average, the elimination T1/2 was prolonged almost three fold in our patients with dialysis-dependent ESRD compared with patients with CrCl > 50 mL/min. In the presence of renal dysfunction, modification of standard dosing regimens may be advisable to avoid prolonged elevated plasma levels of aprotinin.

Aprotinin is a small, basic polypeptide completely filtered in the glomerulus and metabolized by lysosomal enzymes in the proximal convoluted tubule (7,8). Filtered aprotinin is completely metabolized in the proximal tubule, because no biologically active metabolites are found in urine (2,9). Additionally, only 4% of radiolabeled aprotinin is found in the liver, which suggests that hepatic metabolism is probably insignificant. Elimination is therefore almost entirely renal, and the presence of renal dysfunction should predictably diminish ApCl and prolong elimination T1/2. Unfortunately, there is little information regarding aprotinin pharmacokinetics in cardiac surgical patients with normal renal function undergoing CPB and none for cardiac surgical patients with renal insufficiency or ESRD. Although the safe use of aprotinin has been reported in a small series of cardiac surgical patients with ESRD (10), neither plasma levels nor pharmacokinetic data were provided. We previously demonstrated reduced aprotinin clearance in a patient with ESRD undergoing CPB (3), a finding that prompted our current investigation of aprotinin elimination pharmacokinetics in patients with normal and abnormal renal function undergoing CPB.

Levy et al. (11) assessed pharmacokinetic variables after a single IV aprotinin dose of 1 or 0.5 million KIU administered to 28 patients with normal renal function 48 hours before cardiac surgery. They reported a mean elimination clearance of 35.5 mL/min (11). Schall et al. (12,13) reviewed the pharmacokinetics of aprotinin in 47 patients undergoing gynecologic surgery. After loading doses of 1 or 2 million KIU, they reported mean ApCl values between 39–50 mL/min and elimination T1/2 between 5.3 and 8.3 hours. In another evaluation of 131I-labeled aprotinin administered to healthy volunteers, Kaller et al. (14) noted an elimination T1/2 of seven hours. These figures are consistent with data obtained in our study from patients with preserved renal function (CrCl > 50 mL/min), where mean ApCl and elimination T1/2 were 53 mL/min and 7.8 hours, respectively.

In contrast to healthy subjects, Bianchi et al. (9) employed very small doses of 99mTc-labeled aprotinin to image the kidney in 22 patients with varying degrees of renal insufficiency. Using a two-compartment model of aprotinin elimination, they reported ApCl values and a linear regression analysis of ApCl and glomerular filtration rate, that were nearly identical to results we obtained in this study. Rustom et al. (15) investigated the elimination of radiolabeled aprotinin in 9 patients with renal insufficiency (mean CrCl 40 mL/min) and found a mean ApCl of 38 mL/min, which is also similar to the value of 34 mL/min we observed in Group 3 patients (mean CrCl 44 mL/min). Finally, data from a brief report by Müller et al. (16), on the pharmacokinetics of aprotinin in two patients with renal insufficiency undergoing gynecologic surgery, revealed T1/2 of 13.3 and 14.9 hours, respectively. Thus, our findings are in agreement with elimination pharmacokinetic values obtained in noncardiac surgical patients with renal insufficiency receiving a single dose of aprotinin.

Our investigation reveals a linear relationship between CrCl and ApCl (Figure 1). However, in an effort to establish possible values for CrCl that would be clinically useful as a guide to possible dosing alterations, we further analyzed the data according to subgroups of CrCl. This subgroup analysis suggests that for CrCl > 50 mL/min, alterations in dosing are probably unnecessary. Although our study cannot define a lower threshold of CrCl for dose modification, a reduction in dosing appears to be appropriate for patients with severe renal impairment in whom clearance is reduced significantly and T1/2 is markedly prolonged.

Unfortunately, neither the optimum dose of aprotinin nor the appropriate therapeutic concentrations required for effective hemostasis have been definitively established. Although theoretical calculations from experimental in vitro models suggest that levels of approximately 200 and 50 KIU/mL are necessary to inhibit plasma kallikrein and plasmin, respectively (17,18,2), the effective concentrations required in vivo may be substantially different depending on the complex interactions of the hemostatic system (17). In fact, significant blood-sparing effects and improvements in platelet function and indices of fibrinolysis have been demonstrated using small-dose aprotinin (11,19–26). We chose the standard loading dose of 2 million KIU to rapidly achieve satisfactory plasma concentrations of aprotinin. The reduced infusion rate of 0.25 million KIU/h (the so-called "half-Hammersmith" infusion rate), along with exclusion of the pump prime dose, seemed appropriate dosing modifications for our study because of the potential for impaired elimination of aprotinin in patients with renal dysfunction. The levels we obtained (Figure 4) were consistent with values from patients with normal renal function reported by Von Oeveren et al. (27) and Dietrich et al. (28) using full- and half-Hammersmith dosing schedules, respectively, although the extreme variability of reported aprotinin plasma levels using different dosing regimens and assay techniques makes valid comparisons with other studies problematic (11,28,29,30,31).

Although the findings from previous investigations of healthy volunteers and patients with renal insufficiency agree with our own data, they were obtained after the administration of only a single dose of aprotinin to subjects undergoing noncardiac surgery. They are not strictly comparable to cardiac surgical patients because of the absence of possible confounding effects of pharmacokinetic alterations induced by CPB. However, the similarity of our elimination kinetics to those obtained in these studies suggests a negligible influence of CPB on aprotinin elimination, and a consistent reduction in clearance caused by changes in glomerular filtration rate.

The impact of CPB on drug elimination is complex, and the dynamic interplay of hemodilution, hypothermia, alterations in protein binding, drug sequestration by the lungs, changes in renal and hepatic blood flow, and altered volumes of distribution caused by hemorrhage and fluid administration may unpredictably alter drug elimination during cardiac surgery (32,33). To control the possible influence of these variables on ApCl, baseline measures of weight, the duration of CPB, the extent and duration of hypothermia, acid-base changes during CPB, perioperative blood and fluid administration, and perioperative cardiac index (as a surrogate for renal blood flow), were compared between groups to exclude factors other than CrCl that may have influenced aprotinin elimination (Table 1). This analysis revealed albumin concentrations that were predictably lower in patients with ESRD, although the impact of protein binding on plasma aprotinin levels should be minimal because little aprotinin is protein bound (7). As anticipated, perioperative BUN and creatinine values were significantly higher in patients with ESRD at each day but were unchanged within groups from preoperative values up to three days postoperatively. All other variables were similar between groups except for CPB duration, which was significantly longer in Group 2 versus Group 3 patients, and intraoperative packed red blood cells transfusion, which was greater in Group 2 versus Group 4 patients. While the latter difference might be expected to diminish aprotinin levels (via dilutional changes) and thus increase the calculated ApCl in Group 2, the opposite effect was observed. The impact of a longer duration of CPB in this same group is, however, unclear.

The pharmacokinetic analysis of drug elimination during and after CPB is restricted by the absence of true steady-state conditions, which are considered important for accurate measurements of drug elimination and the creation of pharmacokinetic models (33). However, we measured aprotinin concentrations and elimination parameters for 26 to 30 hours after discontinuation of the aprotinin infusion and completion of CPB, thereby encompassing a period of roughly three to five half-lives of aprotinin. Although this approach permits reliable measurement of terminal elimination T1/2, it precludes determination of the initial distribution T1/2, which would instead require frequent sampling of plasma concentrations immediately after administration of the loading dose (6). It also limits any conclusions regarding the appropriate application of a two- or three-compartment model to the pharmacokinetics of aprotinin. Clearance, however, can be accurately calculated without using compartmental models. Instead, noncompartmental models can be used to determine clearance by dividing the total drug dose by the AUC from zero to infinity (6).

Because of findings obtained from a limited number of clinical investigations, controversy has developed regarding the potential nephrotoxic effects of aprotinin (34,35). However, data from several large clinical studies failed to demonstrate an adverse effect of aprotinin on renal function, even in patients with mild elevations in baseline serum creatinine (23,36–38). In addition, the reported changes in serum creatinine from the former studies were conservatively estimated as >0.5 mg/dL increases in postoperative creatinine levels, an incremental difference unlikely to be of clinical significance. Based on prior clinical evidence that failed to demonstrate nephrotoxic effects of aprotinin, and based on the lower total aprotinin dose we administered, we considered our study protocol safe for patients with renal insufficiency. Our study contains too few patients to satisfactorily assess the impact of aprotinin therapy on postoperative renal function in patients with either normal or abnormal renal function. Moreover, this was a pharmacokinetic investigation that was not designed to assess the potential nephrotoxicity of aprotinin.

An additional concern in cardiac surgical patients with reduced aprotinin elimination was the potential development of a prothrombotic state caused by persistent biologically effective concentrations of aprotinin at 24 hours. Nonetheless, despite a prolonged T1/2 in Groups 1 and 2, TEG analysis revealed maximal amplitude, reaction time, and the clot lysis index at 30 minute values at 24 hours that were unchanged compared with baseline values. Although TEG may be an unproven measure of clinical hypercoagulability, it was reassuring to demonstrate an unchanged in vivo whole blood coagulation profile in patients with reduced ApCl. It is possible, however, that full-dose aprotinin therapy may produce abnormal TEG results if higher concentrations of aprotinin are achieved in patients with renal dysfunction. In addition, although it is unknown whether elevated plasma aprotinin concentrations associated with unmodified full-dose therapy in patients with significant renal dysfunction are associated with adverse sequela, less drug (and thus cost) is probably required to achieve plasma levels comparable to those obtained with standard dosing in patients with normal renal function.

The fundamental conclusions of our investigation are based on the significant relationship between CrCl and ApCl demonstrated by regression analysis (Figure 1), and are not dependent on specific subgroupings of CrCl. However, the small sample size precludes specific conclusions regarding dosing modification based on CrCl. Further study of a larger series of patients with renal dysfunction using predetermined target plasma aprotinin levels will be necessary to establish definitive dosing guidelines based on renal function.

In summary, our data demonstrate that ApCl is reduced and aprotinin elimination T1/2 is prolonged in cardiac surgical patients with impaired renal function undergoing CPB. Based on our findings, modification of standard cardiac surgical dosing may be appropriate in patients with significant renal dysfunction. A reduction in the infusion rate to 0.25 million KIU/h and elimination of the pump prime dose, as used in this study, appear to be acceptable modifications of standard dosing regimens.


   Acknowledgments
 
This study was supported, in part, by a grant from the Bayer Co., West Haven, CT.

The authors gratefully acknowledge the assistance of Robert McCarthy, PharmD, with the analysis of pharmacokinetic parameters.


   References
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 

  1. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg 1997;85:1258–67.[Abstract]
  2. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneim-Forsch 1983;33:479–94.[Medline]
  3. O’Connor CJ, McCarthy R, Barnes S, Tuman KJ. The effect of chronic renal failure on plasma aprotinin levels during cardiac surgery. Anesth Analg 1997;85:763–5.[Medline]
  4. Robert S, Zarowitz BJ, Peterson EL, Dumler F. Predictability of creatinine clearance estimates in critically ill patients. Crit Care Med 1993;21:1487–95.[Web of Science][Medline]
  5. Gallimore MJ, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein like activity in human plasma. Thromb Res 1982;25:293–9.[Web of Science][Medline]
  6. Shargel L, Yu A. Applied biopharmaceutics and pharmacokinetics. 4th ed. Stanford:Appleton & Lange, 1999.
  7. Tenstad O, Williamson HE, Clausen G, et al. Glomerular filtration and tubular absorption of the basic polypeptide aprotinin. Acta Physiol Scand 1994;152:33–50.[Web of Science][Medline]
  8. Rustom R, Grime JS, Maltby P, et al. Observations on the early renal uptake and later tubular metabolism of radiolabelled aprotinin (Trasylol) in man: theoretical and practical considerations. Clin Sci 1993;84:231–5.[Medline]
  9. Bianchi C, Donadio C, Gianfranco T, et al. 99mTc-aprotinin: a new tracer for kidney morphology and function. Eur J Nucl Med 1984;9:257–60.[Medline]
  10. Lemmer JH Jr., Metzdorff MT, Krause Ah, et al. Aprotinin use in patients with dialysis-dependent renal failure undergoing cardiac operations. J Thorac Cardiovasc Surg 1996;112:192–4.[Free Full Text]
  11. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013–8.[Web of Science][Medline]
  12. Schall R, Muller FO, Hundt HKL, et al. Pharmacokinetic profile of high doses of aprotinin in patients undergoing primary elective hysterectomy: a meta-analysis of two clinical trials. Drug Invest 1994;7:200–8.
  13. Schall R, Groenewoud G, Hundt HKL, et al. Pharmacokinetic profile of aprotinin (Trasylol®) in female patients undergoing primary elective hysterectomy. Drug Invest 1992;4:292–9.
  14. Kaller H, Patzschke K, Wegner LA, Horster FA. Pharmacokinetic observations following intravenous administration of radioactive labelled aprotinin in volunteers. Pharmacokinet 1978;2:79–85.
  15. Rustom R, Grime JS, Maltby P, et al. Renal tubular protein degradation of radiolabelled aprotinin (Trasylol®) in patients with chronic renal failure. Clin Sci 1993;85:733–6.[Medline]
  16. Müller FO, Schall R, Hundt HKL, et al. Pharmacokinetics of aprotinin in two patients with chronic renal impairment. Clin Pharmacol 1996;41:619–20.
  17. Royston D. High-dose aprotinin therapy: a review of the first five years’ experience. J Cardiothorac Vasc Anesth 1992;6:76–100.[Medline]
  18. Philipp E. Calculations and hypothetical considerations on the inhibition of plasmin and plasma kallikrein by Trasylol®. In: Davidson JF, Rowan RM, Samama MM, Desnoyers PC, eds. Progress in chemical fibrinolysis and thrombolysis. New York:Raven Press, 1978:291–5.
  19. Misfeld M, Dubbert S, Eleftheriadis S, et al. Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations. Ann Thorac Surg 1998;66:792–9.[Abstract/Free Full Text]
  20. Hardy JF, Belisle S, Couturier A, Robitaille D. Randomized, placebo-controlled, double blind study of an ultra-low-dose aprotinin regimen in reoperative and/or complex cardiac operations. J Card Surg 1997;12:15–22.[Web of Science][Medline]
  21. Lavee J, Raviv Z, Smolinsky A, et al. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1993;55:114–9.[Abstract]
  22. Liu B, Tengborn L, Larson G, et al. Half-dose aprotinin preserves hemostatic function in patients undergoing bypass operations. Ann Thorac Surg 1995;59:1534–40.[Abstract/Free Full Text]
  23. Levy JH, Pifarre R, Schaff NV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236–44.[Abstract/Free Full Text]
  24. Wildevuur Ch. RH, Eijsman L, Roozendaal KJ, et al. Platelet preservation during cardiopulmonary bypass with aprotinin. Cardiothorac Surg 1989;3:533–8.
  25. Lemmer JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996;62:1659–68.[Abstract/Free Full Text]
  26. Shigeta O, Kojima H, Jikuya T, et al. Aprotinin inhibits plasmin-induced platelet activation during cardiopulmonary bypass. Circulation 1997;96:569–74.[Abstract/Free Full Text]
  27. van Oeveren W, Jansen NJG, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Thorac Surg 1987;44:640–5.[Abstract]
  28. Dietrich W, Schopf K, Spannagl M, et al. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations. Ann Thorac Surg 1998;65:70–8.[Abstract/Free Full Text]
  29. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364–72.[Abstract]
  30. Dietrich W, Spannagl M, Jochum M, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119–26.[Web of Science][Medline]
  31. Bennett-Guerrero E, Sorohan JG, Howell ST, et al. Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. Anesth Analg 1996;83:1189–92.[Abstract]
  32. Rosen DA, Rosen KR. Elimination of drugs and toxins during cardiopulmonary bypass. Cardiothorac Vasc Anesth 1997;11:337–40.
  33. Buylaert WA, Herregods LL, Mortier EP, Bogaert MG. Cardiopulmonary bypass and the pharmacokinetics of drugs: an update. Clin Pharmacokinet 1989;17 (1):10–26.[Web of Science][Medline]
  34. D’Ambra MN, Akins CW, Blackstone EH, et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. Cardiovasc Surg 1996;112:1081–9.
  35. Sundt TM, Kouchoukos NT, Saffitz JE, et al. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418–24.[Abstract]
  36. Hayashida N, Isomura T, Sato T, et al. Effects of minimal-dose aprotinin on coronary artery bypass grafting. Cardiovasc Surg 1997;114:261–9.
  37. Dietrich W, Barankay A, Hahnel , Richter JA. High-dose aprotinin in cardiac surgery: three years’ experience in 1,784 patients. J Cardiothorac Vasc Anesth 1992;6:324–7.[Medline]
  38. Lemmer JH Jr., Stanford W, Bonney SL, et al. Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 1995;59 (1):132–6.[Abstract/Free Full Text]
Accepted for publication July 6, 1999.




This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
S. C. Body and C. D. Mazer
Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery
Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
E. H. Kincaid, D. A. Ashburn, J. R. Hoyle, M. G. Reichert, J. W. Hammon, and N. D. Kon
Does the Combination of Aprotinin and Angiotensin-Converting Enzyme Inhibitor Cause Renal Failure After Cardiac Surgery?
Ann. Thorac. Surg., October 1, 2005; 80(4): 1388 - 1393.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
G. A. Nuttall, D. N. Fass, L. J. Oyen, W. C. Oliver Jr., and M. H. Ereth
A Study of a Weight-Adjusted Aprotinin Dosing Schedule During Cardiac Surgery
Anesth. Analg., February 1, 2002; 94(2): 283 - 289.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
D. Royston, R. Cardigan, C. Gippner-Steppert, and M. Jochum
Is Perioperative Plasma Aprotinin Concentration More Predictable and Constant After a Weight-Related Dose Regimen?
Anesth. Analg., April 1, 2001; 92(4): 830 - 836.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
G. Ekback, K. Axelsson, L. Ryttberg, B. Edlund, J. Kjellberg, J. Weckstrom, O. Carlsson, and U. Schott
Tranexamic Acid Reduces Blood Loss in Total Hip Replacement Surgery
Anesth. Analg., October 1, 2000; 91(5): 1124 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
S. M. Beath, G. A. Nuttall, D. N. Fass, W. C. Oliver Jr., M. H. Ereth, and L. J. Oyen
Plasma Aprotinin Concentrations During Cardiac Surgery: Full- Versus Half-Dose Regimens
Anesth. Analg., August 1, 2000; 91(2): 257 - 264.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
C. J. O'Connor, D. Roozeboom, R. Brown, and K. J. Tuman
Pulmonary Thromboembolism During Liver Transplantation: Possible Association with Antifibrinolytic Drugs and Novel Treatment Options
Anesth. Analg., August 1, 2000; 91(2): 296 - 299.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Connor, C. J.
Right arrow Articles by Tuman, K. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Connor, C. J.
Right arrow Articles by Tuman, K. J.

Lippincott, Williams & Wilkins Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999 HighWire Press